Intraperitoneal Atomization of Ropivacaine During Gynecologic Laparoscopic Surgery
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Pain following laparoscopic surgery continues to be a clinically important problem with 80%
or more patients requiring opioid analgesia post-operatively to control their pain. By
reducing this surgical complication patients can experience less discomfort and be discharged
from the recovery room more rapidly leading to reduced resource utilization and expense.
HYPOTHESIS: Post-operative pain after laparoscopic procedures could be treated by topical
anesthetics sprayed directly into the abdomen (inside the abdominal cavity, on the nerve
endings of the visceral peritoneal lining and diaphragm surface) via the surgical incision
METHODS: Randomized controlled trial on use of topical anesthetic (namely 0.25% ropivacaine)
delivered directly onto the target sites both at the beginning and the end of surgery in
patients undergoing laparoscopic gynecologic procedure for uterine or adnexal benign
pathology. The drug will be delivered using a CE approved delivery system that will direct a
fine mist of drug directly to the areas of the peritoneal cavity that are theoretically the
cause of post-op pain (diaphragms, peritoneal abdominal surface, surgical dissection site).
GOAL: to assess the efficacy of intraperitoneal topical anesthesia in reducing postoperative
pain, opioid requirements in patients undergoing laparoscopic gynecologic procedure for
uterine or adnexal benign pathology